METHUSELAH ARCHIVE INTERVENTIONS / GEROVITAL H3 (PROCAINE ANTI-AGING THERAPY)

Gerovital H3 (procaine anti-aging therapy)

injection · 1951–1988
category:injection
delivery:Courses of buffered, stabilized procaine hydrochloride, given mainly as a series of intramuscular injections (a typical course was a fixed number of injections repeated in cycles over the year), with an oral tablet form also marketed. Gerovital H3 is a roughly two percent procaine hydrochloride solution with benzoic acid, potassium metabisulfite, and disodium phosphate as stabilizers (about pH 3.3), procaine being the major component. Treatment was delivered at Ana Aslan's Bucharest institute and associated clinics, and the program drew foreign patients to Romania for courses of treatment.
price tier:elite
era:1951–1988
current status:both
regulatory:off_label
SHORT PITCH (AS SOLD)
A course of injected (or oral) buffered procaine, branded Gerovital H3, sold as a systemic treatment to slow aging, treat the diseases of later life, and restore the vitality of youth.
THE ACTUAL EVIDENCE
Aslan's own 1965 animal study reported extended lifespan in procaine-treated rats, but the human evidence did not hold up. The 1977 Ostfeld, Smith, and Stotsky review in the *Journal of the American Geriatrics Society* evaluated 285 articles and books describing treatment of more than 100,000 patients over 25 years and concluded that, except for a possible antidepressant effect, there is no convincing evidence that procaine or Gerovital has any value in the treatment of disease in older patients. Procaine is rapidly hydrolyzed to para-aminobenzoic acid and diethylaminoethanol; the only plausible systemic action identified was weak, reversible monoamine oxidase inhibition. The US FDA classified the Gerovital H3 anti-aging product as an unapproved new drug and acted against its importation in 1982, and Perls (2013) restated that no scientifically credible evidence supports procaine for age-related disease.
PRACTITIONERS
INGREDIENTS
CASES
CLAIMS
SOURCES
  1. Preventive treatment and cure of aging phenomena; action of novocaine as eutrophic and rejuvenating factor (1957)
  2. Long-term treatment with procaine (Gerovital H3) in albino rats (1965)
  3. The systemic use of procaine in the treatment of the elderly: a review (1977)
  4. The Reappearance of Procaine Hydrochloride (Gerovital H3) for Antiaging (2013)
  5. The Radioprotective Effect of Procaine and Procaine-Derived Product Gerovital H3 in Lymphocytes from Young and Aged Individuals (2020)
NOTES

Gerovital H3 was the mid-twentieth-century state-scientific entry in the rejuvenation tradition: buffered procaine, the local anesthetic Novocain repurposed as a systemic anti-aging agent. Developed by Constantin Ion Parhon and Ana Aslan in Bucharest from around 1949 to 1951 and produced and administered through Aslan’s National Institute of Geriatrics and Gerontology, it was given as courses of injections (and later oral tablets) and promoted to slow aging, treat the chronic diseases of later life, and restore the energy, mood, and appearance of youth. The program made Romania a destination for foreign patients seeking the treatment.

The intervention shares the structure of the earlier injection-and-extract rejuvenation cases in this archive (Brown-Sequard’s testicular extract, Voronoff’s grafts, Niehans’s fetal cells, Bogomolets’s serum): a substance proposed to reverse aging on a mechanism the biology did not support, promoted by the developer who also produced and validated it. The disconfirmation came from the controlled clinical literature rather than from a single dramatic event: the 1977 Ostfeld, Smith, and Stotsky review of more than 100,000 treated patients found no anti-aging or disease value beyond a possible antidepressant effect. The US FDA treated the anti-aging product as an unapproved new drug and acted against its import in 1982. The Gerovital name survives today on two tracks: a procaine-free Romanian cosmetic line (Farmec), and a procaine medicine, a 2% procaine hydrochloride Gerovital H3 injectable bearing Aslan’s name and manufactured by Zentiva, documented as commercially available under a Romanian marketing authorization (no. 1583/2012/01) in Ungurianu et al (2020). The same evidence gap reaches the product sold today: the current Zentiva injectable is the same roughly 2% procaine the controlled literature already evaluated, and a search of the post-2013 literature finds no randomized trial, systematic review, or clinical guideline supporting an anti-aging or disease-preventing benefit; the recent work treats procaine only as a candidate antioxidant in cell and animal models (Ungurianu et al 2020), and the US FDA still classifies the anti-aging product as an unapproved new drug after its 1982 action (Perls 2013). The Romanian marketing authorization makes the injectable a lawful medicinal product, not a proven anti-aging one; the Farmec line is a separate, procaine-free cosmetic range the cited clinical literature does not address.